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min  4, and female gender had a trend towards higher nadir
MDASI scores (see Table 1). Other pre-transplant variables, in-
cluding Durie-Salmon stage, LDH, hemoglobin, disease status at
time of autograft, and time from diagnosis to autograft had no
apparent correlation with symptom burden throughout transplant
(data not shown). Conclusions: Autografting for MM is associated
with signiﬁcant but reversible symptom burden during the ﬁrst 30
days of the procedure. Baseline symptom burden is the most
important predictor of post transplant symptom burden. Other
potential predictors include Charlson score, age, 2M, albumin,
and female gender. The MDASI scoring system is a potentially
useful means of following symptom burden post autografting that
could be used to assess interventions aimed at reducing transplant
related morbidity in MM patients (Table 1).
Table 1. Impact of Pre-transplant Variables on Nadir MDASI Scores
n Median (range) P value
Charlson score
<3 50 22 (1–97)
>3 14 41 (3–72) .09
Age
<60 43 23 (1–97)
>60 21 31 (3–72) .2
2M
< 3.0 34 20 (1–85)
>3.0 27 28 (4–97) .2
Albumin
< 4.0 50 27 (1–97)
> 4.0 14 19 (1–60) .2
Gender
Female 26 30 (5–85)
Male 38 23 (1–97) .2
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BLOOD AND MARROW TRANSPLANT CAREGIVER ORIENTATION AND
RESOURCE FAMILY PROGRAM
Jensen, S.L.1, Mignone, T.1, McCarthy, P.M.1 Roswell Park Cancer
Institute, Buffalo, NY.
Treatment advances have resulted in a dramatic increase in the
number of patients who survive hematological malignancies
through blood and marrow transplant, but the psychosocial aspects
of transplant and the emotional sequelae for the patient and the
family can be devastating. A number of studies have reported
signiﬁcantly increased rates of depression, anxiety, sexual dysfunc-
tion, and fatigue among the transplant population (eg, Antin, J.,
2002). Our experience has documented the need for a structured
program to prepare families for the challenges of the transplant
process.
The BMT Caregiver Orientation and Resource Family Pro-
gram. The goals of the Program:
• Help the caregiver to understand the patient’s medical/emo-
tional needs.
• Provide information to the caregiver so they can provide ade-
quate care to the patient.
• Assist the caregiver and patient in identifying and utilizing a list
of personal resources to help in the care of the patient. Provide
support to the caregivers, families, and patients.
BMT Caregiver Program: Each family receives a personalized
care manual during a two hour workshop for patients and caregiv-
ers. The workshop:
• Details the medical, psychological, and social implications of
transplant.
• Introduces them to their transplant team and their Resource
Family
• Helps them complete portions of their Family Workbook with
medical team present.
• Helps them understand the critical nature of caregiver support
and the importance of identifying and ameliorating caregiver
fatigue.
Resource Family Program: Resource Families are past trans-
plant patient families that have successfully navigated the rigors of
the disease treatment process. These families are educated to work
with new transplant patients and their families. Speciﬁc ways in
which the Resource Families help include:
• Sharing transplant experiences.
• Identifying and understanding stressors caregivers may encounter.
• Introducing techniques to manage the stress of the patient’s
illness and treatment.
The importance of preparing patients and their caregivers for the
care required after transplant cannot be understated and has a
direct relationship to the success of the transplant. This program
integrates the critical support needs of the caregiver with the
patient’s ongoing care. Program evaluation has been built into the
program to assess effectiveness. The current evaluation data, which
includes suggestions for program modiﬁcations from transplant
families, will be discussed.
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A QUALITY MANAGEMENT PROGRAM’S (QMP) FAVORABLE IMPACT ON
A HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) PRACTICE: THE
UNIVERSITY OF KANSAS MEDICAL CENTER EXPERIENCE
Deauna-Limayo, D.1, Shik, N.1, Merkel, D.1, Harvey, E.1,
Divine, C.1, Folker, T.1, Lewis, J.1, Hoffmann, T.1, Sherman, J.1,
Bradley, M.1, Skikne, B.1 The University of Kansas Medical Center,
Kansas City, KS.
HSCT remains the only curative option for some hematologic
disorders. However, it is associated with signiﬁcant toxicities. The
100-day transplant-related mortality (TRM) may range from 3 to
10% and 20 to 50%, among autologous and allogeneic transplant
recipients, respectively. We present the QMP’s favorable impact
on our institution’s stem cell transplant outcomes. QMP reorga-
nization was done pursuant to the Foundation for the Accredita-
tion of Cellular Therapy (FACT) standards. Transplant-related
aspects of care were identiﬁed and divided into 4 groups: clinical,
data management, data collection, and ﬁnancial. Members were
expanded, and active participation from our Infectious Control
service was solicited. Monthly audits of indicators from assigned
aspect of care were conducted. Outcome analyses of data gathered
from 2002 to 2004 were done. Internal and CIBMTR data served
as benchmarks. Internal audit(s) revealed infection as the leading
cause of early (30 days) TRM among 9/16 patients who under-
went allogeneic transplantation from September 2002 to Decem-
ber 2003, with documented bloodstream infection (BSI) in 55% of
the patients. A signiﬁcant increase in BSI during the fourth quarter
of 2004 were noted among patients in the Cancer/HSCT services
at 5.22 compared to 1.67/1000 patient days (internal benchmark).
Clostridium difﬁcile was increased in 2003, especially among HSCT
recipients: 11.8 versus 3.6/1,000 pt days in 2002. Working in close
collaboration with our Infectious Control service, contributory
factors were identiﬁed and changes implemented to improve out-
comes: construction of additional interventional radiology suite for
central venous catheter placement, especially for immunocompro-
mised patients, alteration of dressing change techniques, updating
of infection control policies, and hiring of a dedicated transplant
nurse practitioner. Follow-up data revealed a decrease of BSI
to1.72/1,000 pt days in the ﬁrst quarter 2005. C. difﬁcile incidence
trended down to 10/1000 pt days in 2004. The 2003 and 2004
100-day TRM showed signiﬁcant decrease from 18% to 4%
among autologous and 45% to 20% for allogeneic transplant
recipients, respectively. Median neutrophil and platelet engraft-
ments were 11.4 and 17 days for autologous transplants, and 16.5
and 21 days for allogeneic transplants, at par with CIBMTR data
serving as benchmark. In summary, reorganization of our QMP
favorably impacted our transplant practice. A multi-disciplinary
approach is essential.
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